Bryan Irving is now executive vice president and chief scientific officer of Five Prime Therapeutics (NASDAQ: [[ticker:FPRX]]). Irving first joined South San Francisco-based Five Prime last year as vice president of research. His experience also includes posts at CytomX Therapeutics (NASDAQ: [[ticker:CTMX]]) and Genentech. Clinical-stage Five Prime develops protein therapies to treat cancer and inflammatory diseases.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
